Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging92
Best of 2022 in prostate cancer and prostatic diseases86
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?76
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?69
New BPH therapy classification: what really FITs?58
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis58
More evidence that physical activity is beneficial for prostate cancer55
Sexual outcomes in men who have sex with men who underwent radical prostatectomy52
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer49
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States42
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction41
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study38
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study37
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions37
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)36
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro36
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer35
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes34
Concerns regarding prostate cancer screening guidelines in minority populations33
Germline alterations among Hispanic men with prostate cancer32
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches30
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis30
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts29
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations29
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer29
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer29
Incidence of prostate cancer in transgender women in the US: a large database analysis29
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer29
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study28
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients28
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis28
0.89619612693787